 Tucked in the Q2 earnings release, Sage Therapeutics Inc NASDAQ: SAGE has terminated two long-suspended Phase 3 zuranolone trials in major depressive disorder MDD. What Happened: After talks with the FDA, the decision led the Company to believe it can seek approval without the data. 